• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Odonate Therapeutics, Inc. (Amendment)

    11/22/21 11:08:29 AM ET
    $ODT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ODT alert in real time by email
    SC 13D/A 1 d257373dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13D

    (Rule 13d-101)

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Odonate Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, $0.01 par value

    (Title of Class of Securities)

    676079106

    (CUSIP Number)

    David A. Brown

    Alston & Bird LLP

    950 F Street, N.W.

    Washington, DC 20004-1404

    202-239-3463

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    November 17, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ☐.

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 676079106    SCHEDULE 13D   

     

      1    

      NAMES OF REPORTING PERSONS

     

      Boxer Capital, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

      (a)  ☒        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (See Instructions)

     

      WC

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      4,607,086

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      4,607,086

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      4,607,086

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      12.0%*

    14  

      TYPE OF REPORTING PERSON (See Instructions)

     

      OO

     

    *

    Based on 38,490,336 shares of the Issuer’s Common Stock outstanding as of October 29, 2021 as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.


    CUSIP No. 676079106    SCHEDULE 13D   

     

      1    

      NAMES OF REPORTING PERSONS

     

      Boxer Asset Management Inc.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

      (a)  ☒        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (See Instructions)

     

      AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Bahamas

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      4,607,086

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      4,607,086

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      4,607,086

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      12.0%*

    14  

      TYPE OF REPORTING PERSON (See Instructions)

     

      CO

     

    *

    Based on 38,490,336 shares of the Issuer’s Common Stock outstanding as of October 29, 2021 as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.


    CUSIP No. 676079106    SCHEDULE 13D   

     

      1    

      NAMES OF REPORTING PERSONS

     

      Aaron I. Davis

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

      (a)  ☒        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (See Instructions)

     

      PF

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      445,756

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      445,756

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      445,756

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      1.2%*

    14  

      TYPE OF REPORTING PERSON (See Instructions)

     

      IN

     

    *

    Based on 38,490,336 shares of the Issuer’s Common Stock outstanding as of October 29, 2021 as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.


    CUSIP No. 676079106    SCHEDULE 13D   

     

      1    

      NAMES OF REPORTING PERSONS

     

      Joe Lewis

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

      (a)  ☒        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (See Instructions)

     

      AF

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United Kingdom

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      4,607,086

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      4,607,086

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      4,607,086

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      12.0%*

    14  

      TYPE OF REPORTING PERSON (See Instructions)

     

      IN

     

    *

    Based on 38,490,336 shares of the Issuer’s Common Stock outstanding as of October 29, 2021 as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.


    CUSIP No. 676079106    SCHEDULE 13D   

     

    This Amendment No. 3 (“Amendment No. 3”) amends and supplements the statement on Schedule 13D filed on December 8, 2017 (the “Original Filing”) by Boxer Capital, LLC (“Boxer Capital”), Boxer Asset Management (“Boxer Management”), Aaron I. Davis, and Joe Lewis (together with Boxer Capital, Boxer Management and Mr. Davis, the “Reporting Persons”), as amended by Amendment No. 1, filed by the Reporting Persons on December 27, 2018 and Amendment No. 2, filed by the Reporting Persons on September 1, 2020. The Original Filing, as amended, remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment No. 3. Capitalized terms used and not defined in this Amendment No. 3 have the meanings set forth in the Original Filing, as amended.

     

    Item 5.

    Interest in Securities of the Issuer.

    Item 5 is hereby amended and restated in its entirety as follows:

    (a) The Reporting Persons may be deemed to beneficially own, in the aggregate, 5,052,842 shares of Common Stock, representing 13.1% of the Issuer’s outstanding Common Stock. Boxer Capital, Boxer Management and Joe Lewis beneficially own 4,607,086 shares of Common Stock, which represents 12.0% of the Issuer’s outstanding Common Stock. Aaron I. Davis beneficially owns 445,756 shares of Common Stock, which represents 1.2% of the Issuer’s outstanding Common Stock. All percentages are based on 38,490,336 shares of the Issuer’s Common Stock outstanding as of October 29, 2021 as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.

    (b) With respect to any rights or powers to vote, or to direct the vote of, or to dispose of, or direct the disposition of, the Common Stock owned by the Reporting Persons:

    (i) Sole power to vote or direct the vote:

    Aaron I. Davis has the sole power to vote or to direct the vote of the 445,756 shares of Common Stock he beneficially owns.    

    (ii) Shared power to vote or to direct the vote:

    Boxer Capital, Boxer Management and Joe Lewis have shared power to vote or to direct the vote of the 4,607,086 shares of Common Stock they beneficially own.

    (iii) Sole power to dispose or to direct the disposition of:

    Aaron I. Davis has the sole power to dispose or to direct the disposition of the 445,756 shares of Common Stock he beneficially owns.

    (iv) Shared power to dispose or to direct the disposition of:

    Boxer Capital, Boxer Management and Joe Lewis have shared power to dispose or to direct the disposition of the 4,607,086 shares of Common Stock they beneficially own.

    (c) Other than as set forth below, the Reporting Persons have not engaged in any transactions in the Common Stock in the past 60 days.

    (i) Aaron I. Davis effected the following transactions in the Common Stock in the last 60 days:

     

    Date

       Transaction      Shares of Common Stock      Price Per
    Share
     

    11/17/2021

         Sale        170,000      $ 2.2334  (1) 

    11/19/2021

         Sale        30,000      $ 1.9165  

     

    (1)

    Reflects the weighted average sale price. The range of prices for such transaction is $1.97 to $2.95.

    (2)

    Reflects the weighted average sale price. The range of prices for such transaction is $1.84 to $1.96.

    (ii) Boxer Capital effected the following transactions in the Common Stock in the last 60 days.


    CUSIP No. 676079106    SCHEDULE 13D   

     

    Date

       Transaction      Shares of Common Stock      Price Per
    Share
     

    11/17/2021

         Sale        600,000      $ 2.1654  (1) 

    11/18/2021

         Sale        250,000      $ 1.9490  

    11/19/2021

         Sale        150,000      $ 1.8419  

     

    (1)

    Reflects the weighted average sale price. The range of prices for such transaction is $2.0026 to $2.4018.

    (d) No other person has the right to receive or the power to direct the receipt of dividends, or proceeds of sale of such securities outlined in this report.

    (e) Not applicable.

    Item 7. Material to Be Filed as Exhibits.

     

    Exhibit 1    Joint Filing Agreement, dated December 8, 2017, among Boxer Capital, Boxer Management, Joe Lewis and Aaron I. Davis, incorporated by reference to Exhibit 99.1 to the Schedule 13D filed by the Reporting Persons on December 8, 2017.


    CUSIP No. 676079106    SCHEDULE 13D   

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 22, 2021

     

    BOXER CAPITAL, LLC
    By:  

    /s/Aaron I. Davis

    Name:   Aaron I. Davis
    Title:   Chief Executive Officer
    BOXER ASSET MANAGEMENT INC.
    By:  

    /s/ Jason Callender

    Name:   Jason Callender
    Title:   Director
    JOSEPH C. LEWIS
    By:  

    /s/ Joseph C. Lewis

      Joseph C. Lewis, Individually
    AARON I. DAVIS
    By:  

    /s/ Aaron I. Davis

      Aaron I. Davis, Individually
    Get the next $ODT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ODT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ODT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Odonate Announces Expected Delisting of Its Stock

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. Odonate will not appeal this determination. Therefore, Odonate expects the trading of its common stock on The Nasdaq Stock Market to be suspended at the opening of business on January 18, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the "SEC"), which will remove Odonate's securities from listing and registration on The

      1/7/22 9:00:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders. This action is in connection with the Company's previously announced decision to discontinue the development of tesetaxel. Repurchases may be made from time to time at the Company's discretion. The plan has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases. As of September 30, 2021, as reported in its recently filed Form 10-Q, the Company had total stockholders' equity of $71.4 million, or $1.85 per share, based on 38.5 million shares ou

      11/17/21 7:45:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate's cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively. Odonate's net loss for the three and nine months ended September 30, 2021 was $14.0 million and $69.8 million, or $0.37 and $1.85 per share, respectively, compared to $30.5 million and $94.1 million, or $0.93 and $3.00 per share, respectively, for the same periods in 2020. About Odonate Therapeutics, In

      11/10/21 5:15:00 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Odonate Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded Odonate Therapeutics from Buy to Hold and set a new price target of $4.00 from $45.00 previously

      3/22/21 12:46:40 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics downgraded by Cowen

      Cowen downgraded Odonate Therapeutics from Outperform to Market Perform

      3/22/21 11:27:45 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Ecor1 Capital, Llc bought $308,662 worth of shares (185,941 units at $1.66) and sold $9,741,063 worth of shares (5,887,610 units at $1.65)

      4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

      12/10/21 6:50:07 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Boxer Capital, Llc sold $623,340 worth of shares (400,000 units at $1.56)

      4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

      11/24/21 6:00:33 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Davis Aaron I. sold $2,499,948 worth of shares (1,200,000 units at $2.08)

      4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

      11/19/21 7:22:38 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Odonate Therapeutics Inc.

      25-NSE - Odonate Therapeutics, Inc. (0001717452) (Subject)

      1/25/22 5:30:50 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics, Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)

      1/7/22 9:00:35 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)

      11/18/21 5:00:34 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    Financials

    Live finance-specific insights

    See more

    $ODT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate's cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively. Odonate's net loss for the three and nine months ended September 30, 2021 was $14.0 million and $69.8 million, or $0.37 and $1.85 per share, respectively, compared to $30.5 million and $94.1 million, or $0.93 and $3.00 per share, respectively, for the same periods in 2020. About Odonate Therapeutics, In

      11/10/21 5:15:00 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and six months ended June 30, 2021. In March 2021, Odonate announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. As of June 30, 2021, Odonate has transitioned all patients in tesetaxel studies to appropriate alternative therapies or facilitated continuation of treatment with tesetaxel under compassionate use programs where appropriate. As of June 30, 2021, Odonate had $110.1 million in cash compared to $157.3 million as of December 31, 2020. This decrease in cash resulted primarily from cash used in operating activities for the six months en

      7/27/21 8:30:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three months ended March 31, 2021. Odonate recently announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. Odonate is working with clinical sites to transition patients in ongoing tesetaxel studies to appropriate alternative therapies or facilitate continuation of treatment with tesetaxel under compassionate use programs where appropriate. As of March 31, 2021, Odonate had $133.2 million in cash compared to $157.3 million as of December 31, 2020. This decrease in cash resulted primarily from cash used in operating activities for the three months en

      5/14/21 8:30:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Odonate Therapeutics, Inc. (Amendment)

      SC 13G/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

      12/10/21 5:24:12 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Odonate Therapeutics, Inc. (Amendment)

      SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

      11/26/21 5:01:04 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Odonate Therapeutics, Inc. (Amendment)

      SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

      11/22/21 11:08:29 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care